Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
At this year’s European Congress of Radiology (ECR) in Vienna, Bayer presented new data on a contrast agent that could ...
CORVALLIS, Ore. (KTVZ) -– Scientists at Oregon State University have filed a patent on a design for a new magnetic resonance imaging contrast agent with the potential to outperform current agents ...
The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants. Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective ...
According to MarketsandMarkets™, the Contrast Media Market is projected to grow from about USD 7.65 billion in 2025 to USD 12.08 billion by 2031, at a CAGR of 7.9%.
In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found that a new imaging ...
Bayer submitted an application to the U.S.'s Food and Drug Administration to get approval for its gadoquatrane agent, a substance used to improve the quality of magnetic resonance imaging scans. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results